Advice
in the absence of a submission from the holder of the marketing authorisation:
tisagenlecleucel (Kymriah®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice624KB (PDF)
Medicine details
- Medicine name:
- tisagenlecleucel (Kymriah)
- SMC ID:
- SMC2566
- Indication:
Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 16 January 2023